Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

• Status: Completed
• Trial end date: 2006-07-17
• Target enrollment: 0
• Participant gender: All

Summary

Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia.

The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Denovo Biopharma LLC; Eli Lilly and Company
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• meet the DSM-IV criteria for schizophrenia as confirmed by modified SCID

Exclusion Criteria:

• meet the full syndromal criteria for other Axis I disorder

• have taken any depot antipsychotic within 4 weeks before screening

• are taking mood-stabilizing agents